Alexandria
All providers
Sign in
Sign up to use European Medicines Agency
Firecrawl Alexandria
Life sciences

European Medicines Agency

EU centralised medicines data from EMA's published data files: authorised medicines (EPAR pages), CHMP and CVMP opinions and withdrawn applications, applications under evaluation, EU orphan designations, EPAR and product documents, and EMA-assessed supply shortages, with EMA attribution on every result.

6 Firecrawl tools use European Medicines Agency
Try in Agent
Is natalizumab authorised through the EU centralised procedure, which products contain it and who holds the marketing authorisation?

Try European Medicines Agency now.

Choose an example or ask your own question.

European Medicines Agency
TRY ASKING
1Request
string

category

string

next_cursor from a previous page with the same filters.

string

Exact EMA product number, e.g. EMEA/H/C/000603. No match is not_found.

5 credits
Codefollows the fields above
const result = await firecrawl.scrape({
  alexandria: {
    provider: "ema-europa-eu",
    capability: "records/medicines",
    options: {
      ema_product_number: "EMEA/H/C/000603",
    },
  },
});
2Response example

This is a sample shape. Press Run to see live data from European Medicines Agency.

{
  "attribution": "Source: European Medicines Agency (EMA), https://www.ema.europa.eu. Reproduced under EMA's legal notice, which requires EMA to be acknowledged as the source: https://www.ema.europa.eu/en/about-us/about-website/legal-notice",
  "data_timestamp": "2026-09-27T18:08:33Z",
  "dataset_records": 2746,
  "next_cursor": null,
  "observed_at_ms": 1790554594287,
  "records": [
    {
      "data": {
        "accelerated_assessment": "No",
        "active_substance": "natalizumab",
        "additional_monitoring": "No",
        "advanced_therapy": "No",
        "atc_code_human": "L04AG03",
        "atcvet_code_veterinary": "",
        "biosimilar": "No",
        "category": "Human",
        "conditional_approval": "No",
        "ema_product_number": "EMEA/H/C/000603",
        "european_commission_decision_date": "18/06/2026",
        "exceptional_circumstances": "No",
        "first_published_date": "02/08/2018",
        "generic": "No",
        "international_non_proprietary_name_common_name": "natalizumab",
        "last_updated_date": "06/07/2026",
        "latest_procedure_affecting_product_information": "VR/0000314828",
        "marketing_authorisation_date": "27/06/2006",
        "marketing_authorisation_developer_applicant_holder": "Biogen Netherlands B.V.",
        "medicine_status": "Authorised",
        "medicine_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri",
        "name_of_medicine": "Tysabri",
        "opinion_adopted_date": "",
        "opinion_status": "",
        "orphan_medicine": "No",
        "patient_safety": "No",
        "pharmacotherapeutic_group_human": "Monoclonal antibodies",
        "pharmacotherapeutic_group_veterinary": "",
        "prime_priority_medicine": "No",
        "refusal_of_marketing_authorisation_date": "",
        "revision_number": "53",
        "species_veterinary": "",
        "start_of_evaluation_date": "",
        "start_of_rolling_review_date": "",
        "suspension_of_marketing_authorisation_date": "",
        "therapeutic_area_mesh": "Multiple Sclerosis",
        "withdrawal_expiry_revocation_lapse_of_marketing_authorisation_date": "",
        "withdrawal_of_application_date": ""
      },
      "ema_product_number": "EMEA/H/C/000603",
      "medicine_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri",
      "name_of_medicine": "Tysabri"
    }
  ],
  "source_url": "https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json",
  "total_matching": 1,
  "withheld_fields": [
    "therapeutic_indication"
  ]
}

Source: European Medicines Agency (EMA), https://www.ema.europa.eu. Reproduced under EMA's legal notice, which requires EMA to be acknowledged as the source. (https://www.ema.europa.eu/en/about-us/about-website/legal-notice)

Firecrawl tools

6

Ready-made Firecrawl tools that call European Medicines Agency.

Uses FDA, European Medicines AgencyDrug recall pharmacy substitution planUse when a hospital pharmacy buyer or pharmacy operations manager learns of a drug recall. Identifies the recalled lots and every affected NDC, checks whether therapeutic alternatives are themselves in shortage in the US and EU, reads the alternative's label for dosing differences, and drafts a substitution and communication plan for nursing and prescribers.5 toolsOpen
Uses FDA, European Medicines Agency, ClinicalTrials.govDrug shortage impact assessmentUse when a hospital pharmacy director or supply chain lead learns a drug is short and needs to plan. Reads the FDA shortage entry, finds alternative labelers and presentations, checks recalls at the affected manufacturer, compares the EU shortage picture and lists clinical trials that depend on the drug.6 toolsOpen
Uses WHO Global Health Observatory, European Medicines Agency, FDA, ClinicalTrials.govEx-US launch market screenUse when a pharma or medtech market-access team is ranking countries for launch after US approval. Pulls WHO disease burden for the indication by country, checks which competitors already hold EU authorisation and US approval, and counts competing trials recruiting in each country, then ranks markets by burden, competition and trial crowding.5 toolsOpen
Uses FDA, European Medicines AgencyGeneric drug supply opportunity scanUse when a generics manufacturer, CDMO or pharma business-development lead is looking for molecules worth entering because supply is fragile. Lines up US and EU shortages for the same ingredient, counts how many labelers and approved applications remain, checks recent quality recalls, and ranks the molecules with the fewest reliable makers.6 toolsOpen
Uses FDA, PubMed and PMC, European Medicines Agency, ClinicalTrials.govPost-marketing safety signal triageUse when a pharmacovigilance lead, medical affairs team or health journalist sees a possible new side effect for a marketed drug. Compares FAERS reaction reports against the current label, checks for published case reports, the EU regulatory status and ongoing trials, and returns a signal triage table with what is labelled, what is new and how strong the evidence is.6 toolsOpen
Uses FDA, PubMed and PMC, ClinicalTrials.gov, European Medicines AgencyAdverse event signal triage for a marketed drugUse when a pharmacovigilance scientist, medical affairs lead or hospital pharmacist sees a possible new safety signal for a marketed drug. Counts FAERS reports for the drug and reaction, checks whether the label already lists it, looks for published case reports and dedicated safety trials, and checks the EU regulatory picture, then rates the signal.6 toolsOpen

Benchmarks

Life sciences benchmarks

Quality, speed and cost, last 24 hours, across every agent call to European Medicines Agency through Alexandria.

Fewer than 20 calls in the last 24 hours, so there is not enough to report yet.

Related providers

Browse the library
//
Get started
//
Give your agent European Medicines Agency.
One API key for the live web and every provider in Alexandria.
Use European Medicines AgencyExplore Alexandria
Are you an AI agent? See setup options